Abstract
The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.1 Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti–HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.2–4
Original language | English |
---|---|
Pages (from-to) | 3043-3045.e1 |
Journal | Clinical Gastroenterology and Hepatology |
Volume | 18 |
Issue number | 13 |
DOIs | |
Publication status | Published - 2020 Dec |
Bibliographical note
Funding Information:Conflicts of interest This author discloses the following: S.H.A. has acted as advisor and lecturer for BMS, Gilead Sciences, MSD, AbbVie, Janssen, Assembly Biosciences, Arbutus Biopharma, GC pharma, and Ildong and has received unrestricted grant from Gilead Sciences for the investigator initiated trials. The remaining authors disclose no conflicts. Funding Supported by GC Pharma Co Ltd.
Funding Information:
Funding Supported by GC Pharma Co Ltd.
Publisher Copyright:
© 2020 AGA Institute
All Science Journal Classification (ASJC) codes
- Hepatology
- Gastroenterology